Compare Stocks → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENTANASDAQ:TLCNASDAQ:VRCANASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$12.13-7.1%$14.61$8.08▼$28.25$256.91M0.54236,494 shs267,889 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsVRCAVerrica Pharmaceuticals$8.67-5.2%$6.57$2.86▼$11.41$367.78M1.82182,898 shs162,721 shsXOMAXOMA$25.51-0.6%$25.17$13.48▼$27.00$296.91M0.5718,959 shs7,231 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-2.10%+1.01%-14.97%+0.54%-48.78%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%VRCAVerrica Pharmaceuticals+0.55%+16.71%+30.71%+68.04%+55.35%XOMAXOMA+3.84%+8.32%+5.25%+10.94%+19.96%Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.4175 of 5 stars3.10.00.04.71.82.50.6TLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals4.1151 of 5 stars3.52.00.04.72.02.50.6XOMAXOMA3.5209 of 5 stars3.52.00.03.01.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals2.17Hold$19.0056.64% UpsideTLCTaiwan LiposomeN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.00Buy$13.5055.71% UpsideXOMAXOMA3.00Buy$57.00123.44% UpsideCurrent Analyst RatingsLatest TLC, XOMA, VRCA, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.005/14/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.005/7/2024ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.005/7/2024ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $22.005/1/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.004/29/2024XOMAXOMALeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2024XOMAXOMASVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$40.004/25/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.004/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 5/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$79.20M3.24N/AN/A$7.84 per share1.55TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43VRCAVerrica Pharmaceuticals$5.12M71.83N/AN/A$0.04 per share216.75XOMAXOMA$5.81M51.09N/AN/A$7.07 per share3.61Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$133.82M-$6.24N/AN/AN/A-180.76%-64.85%-29.28%8/5/2024 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/AVRCAVerrica Pharmaceuticals-$67M-$1.75N/AN/AN/A-905.83%-229.26%-88.77%8/13/2024 (Estimated)XOMAXOMA-$40.83M-$3.92N/AN/AN/A-705.23%-26.00%-14.30%8/13/2024 (Estimated)Latest TLC, XOMA, VRCA, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 million2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A6.436.43TLCTaiwan Liposome0.673.013.01VRCAVerrica Pharmaceuticals29.583.174.49XOMAXOMA1.399.459.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%TLCTaiwan Liposome0.22%VRCAVerrica Pharmaceuticals42.45%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.64%TLCTaiwan LiposomeN/AVRCAVerrica Pharmaceuticals42.60%XOMAXOMA7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals14521.18 million18.29 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableVRCAVerrica Pharmaceuticals10042.42 million24.35 millionOptionableXOMAXOMA1311.64 million10.80 millionOptionableTLC, XOMA, VRCA, and ENTA HeadlinesRecent News About These CompaniesMay 14 at 7:30 AM | globenewswire.comXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQMay 10, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average of $20.97May 9, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comXOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesMay 7, 2024 | zacks.comXoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 2, 2024 | marketbeat.comQ1 2024 Earnings Forecast for XOMA Co. Issued By Leerink Partnrs (NASDAQ:XOMA)May 2, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Rating Reiterated by Leerink PartnrsMay 1, 2024 | marketbeat.comXOMA's (XOMA) Buy Rating Reaffirmed at HC WainwrightApril 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For XOMAApril 29, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Receives New Coverage from Analysts at SVB LeerinkApril 25, 2024 | finance.yahoo.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 25, 2024 | marketbeat.comXOMA's (XOMA) Buy Rating Reiterated at HC WainwrightApril 25, 2024 | globenewswire.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOApril 20, 2024 | finance.yahoo.comXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsApril 3, 2024 | globenewswire.comXOMA Corporation Announces Closing of Tender OfferMarch 21, 2024 | globenewswire.comXOMA Declares Quarterly Preferred Stock DividendsMarch 19, 2024 | globenewswire.comXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.March 13, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 8, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023March 8, 2024 | finance.yahoo.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEnanta PharmaceuticalsNASDAQ:ENTAEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Taiwan LiposomeNASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.